Q5E9B4
PR
Gene name |
EIF2B2 |
Protein name |
Translation initiation factor eIF-2B subunit beta |
Names |
eIF-2B GDP-GTP exchange factor subunit beta |
Species |
Bos taurus (Bovine) |
KEGG Pathway |
bta:513958 |
EC number |
|
Protein Class |
|
Descriptions
The autoinhibited protein was predicted that may have potential autoinhibitory elements via cis-regPred.
Autoinhibitory domains (AIDs)
Target domain |
|
Relief mechanism |
|
Assay |
cis-regPred |
Accessory elements
No accessory elements
Autoinhibited structure
Activated structure
1 structures for Q5E9B4
| Entry ID | Method | Resolution | Chain | Position | Source |
|---|---|---|---|---|---|
| AF-Q5E9B4-F1 | Predicted | AlphaFoldDB |
78 variants for Q5E9B4
| Variant ID(s) | Position | Change | Description | Diseaes Association | Provenance |
|---|---|---|---|---|---|
| rs472342547 | 2 | P>A | No | EVA | |
| rs134313873 | 2 | P>Q | No | EVA | |
| rs474567504 | 4 | A>G | No | EVA | |
| rs460951385 | 4 | A>P | No | EVA | |
| rs463423287 | 5 | A>S | No | EVA | |
| rs480196113 | 9 | S>* | No | EVA | |
| rs480196113 | 9 | S>L | No | EVA | |
| rs459928311 | 9 | S>P | No | EVA | |
| rs480196113 | 9 | S>W | No | EVA | |
| rs448635975 | 10 | E>G | No | EVA | |
| rs468613840 | 12 | S>F | No | EVA | |
| rs437150705 | 14 | R>G | No | EVA | |
| rs433238215 | 16 | E>D | No | EVA | |
| rs464526488 | 16 | E>G | No | EVA | |
| rs464526488 | 16 | E>V | No | EVA | |
| rs472331074 | 17 | S>R | No | EVA | |
| rs452236383 | 17 | S>R | No | EVA | |
| rs454713503 | 19 | V>G | No | EVA | |
| rs434685208 | 19 | V>M | No | EVA | |
| rs474646937 | 23 | K>T | No | EVA | |
| rs443228817 | 24 | R>P | No | EVA | |
| rs470724538 | 27 | G>W | No | EVA | |
| rs439325430 | 28 | R>G | No | EVA | |
| rs1118243418 | 28 | R>K | No | EVA | |
| rs459938899 | 28 | R>S | No | EVA | |
| rs480029166 | 29 | R>G | No | EVA | |
| rs442328984 | 29 | R>H | No | EVA | |
| rs462450345 | 30 | S>R | No | EVA | |
| rs482555374 | 32 | E>A | No | EVA | |
| rs482555374 | 32 | E>V | No | EVA | |
| rs450838395 | 33 | D>A | No | EVA | |
| rs464387676 | 36 | R>P | No | EVA | |
| rs446856283 | 37 | E>G | No | EVA | |
| rs465993007 | 38 | T>A | No | EVA | |
| rs434554213 | 42 | L>V | No | EVA | |
| rs454693792 | 45 | I>L | No | EVA | |
| rs468481239 | 46 | I>L | No | EVA | |
| rs437087636 | 47 | T>P | No | EVA | |
| rs456976017 | 48 | D>H | No | EVA | |
| rs470536205 | 49 | H>L | No | EVA | |
| rs439337611 | 50 | R>L | No | EVA | |
| rs473112690 | 52 | S>I | No | EVA | |
| rs442225299 | 52 | S>R | No | EVA | |
| rs451779579 | 65 | G>A | No | EVA | |
| rs471947678 | 70 | A>D | No | EVA | |
| rs471947678 | 70 | A>G | No | EVA | |
| rs460505579 | 71 | A>G | No | EVA | |
| rs442912241 | 76 | T>A | No | EVA | |
| rs483103154 | 82 | V>A | No | EVA | |
| rs483103154 | 82 | V>E | No | EVA | |
| rs450759682 | 85 | V>E | No | EVA | |
| rs457926588 | 90 | R>P | No | EVA | |
| rs446690739 | 95 | R>G | No | EVA | |
| rs453897917 | 102 | E>D | No | EVA | |
| rs473969937 | 103 | S>C | No | EVA | |
| rs442694554 | 103 | S>T | No | EVA | |
| rs462657239 | 105 | Q>H | No | EVA | |
| rs449300670 | 107 | E>D | No | EVA | |
| rs476294069 | 107 | E>G | No | EVA | |
| rs466063546 | 154 | Q>H | No | EVA | |
| rs452264466 | 154 | Q>P | No | EVA | |
| rs434673043 | 155 | A>G | No | EVA | |
| rs454528759 | 159 | I>T | No | EVA | |
| rs474559500 | 160 | H>D | No | EVA | |
| rs443363421 | 164 | V>G | No | EVA | |
| rs457002569 | 165 | I>T | No | EVA | |
| rs470661159 | 174 | V>G | No | EVA | |
| rs1118265716 | 179 | R>K | No | EVA | |
| rs799947572 | 180 | E>G | No | EVA | |
| rs442432069 | 187 | F>I | No | EVA | |
| rs439825816 | 194 | C>G | No | EVA | |
| rs434273912 | 232 | V>G | No | EVA | |
| rs454106117 | 233 | I>V | No | EVA | |
| rs446981558 | 237 | K>N | No | EVA | |
| rs462383307 | 278 | F>I | No | EVA | |
| rs472822231 | 289 | V>E | No | EVA | |
| rs439919778 | 290 | A>V | No | EVA | |
| rs132854745 | 352 | L>Y | No | EVA |
No associated diseases with Q5E9B4
No regional properties for Q5E9B4
| Type | Name | Position | InterPro Accession |
|---|---|---|---|
| No domain, repeats, and functional sites for Q5E9B4 | |||
2 GO annotations of cellular component
| Name | Definition |
|---|---|
| cytoplasm | The contents of a cell excluding the plasma membrane and nucleus, but including other subcellular structures. |
| eukaryotic translation initiation factor 2B complex | A multisubunit guanine nucleotide exchange factor which catalyzes the exchange of GDP bound to initiation factor eIF2 for GTP, generating active eIF2-GTP. In humans, it is composed of five subunits, alpha, beta, delta, gamma and epsilon. |
4 GO annotations of molecular function
| Name | Definition |
|---|---|
| ATP binding | Binding to ATP, adenosine 5'-triphosphate, a universally important coenzyme and enzyme regulator. |
| GTP binding | Binding to GTP, guanosine triphosphate. |
| guanyl-nucleotide exchange factor activity | Stimulates the exchange of GDP to GTP on a signaling GTPase, changing its conformation to its active form. Guanine nucleotide exchange factors (GEFs) act by stimulating the release of guanosine diphosphate (GDP) to allow binding of guanosine triphosphate (GTP), which is more abundant in the cell under normal cellular physiological conditions. |
| translation initiation factor activity | Functions in the initiation of ribosome-mediated translation of mRNA into a polypeptide. |
6 GO annotations of biological process
| Name | Definition |
|---|---|
| central nervous system development | The process whose specific outcome is the progression of the central nervous system over time, from its formation to the mature structure. The central nervous system is the core nervous system that serves an integrating and coordinating function. In vertebrates it consists of the brain and spinal cord. In those invertebrates with a central nervous system it typically consists of a brain, cerebral ganglia and a nerve cord. |
| myelination | The process in which myelin sheaths are formed and maintained around neurons. Oligodendrocytes in the brain and spinal cord and Schwann cells in the peripheral nervous system wrap axons with compact layers of their plasma membrane. Adjacent myelin segments are separated by a non-myelinated stretch of axon called a node of Ranvier. |
| oligodendrocyte development | The process aimed at the progression of an oligodendrocyte over time, from initial commitment of the cell to a specific fate, to the fully functional differentiated cell. An oligodendrocyte is a type of glial cell involved in myelinating the axons in the central nervous system. |
| ovarian follicle development | The process whose specific outcome is the progression of the ovarian follicle over time, from its formation to the mature structure. |
| T cell receptor signaling pathway | The series of molecular signals initiated by the cross-linking of an antigen receptor on a T cell. |
| translational initiation | The process preceding formation of the peptide bond between the first two amino acids of a protein. This includes the formation of a complex of the ribosome, mRNA or circRNA, and an initiation complex that contains the first aminoacyl-tRNA. |
1 homologous proteins in AiPD
| UniProt AC | Gene Name | Protein Name | Species | Evidence Code |
|---|---|---|---|---|
| P32502 | GCD7 | Translation initiation factor eIF-2B subunit beta | Saccharomyces cerevisiae (strain ATCC 204508 / S288c) (Baker's yeast) | PR |
| 10 | 20 | 30 | 40 | 50 | 60 |
| MPGAAAKGSE | LSERIESFVE | ALKRGGGRRS | SEDMARETLG | LLRRIITDHR | WSNAGELMEL |
| 70 | 80 | 90 | 100 | 110 | 120 |
| IRREGRRMTA | AQPSETTVGN | MVRRVLRIIR | EEYGRLHGRS | DESDQQESLH | KLLTSGGLSE |
| 130 | 140 | 150 | 160 | 170 | 180 |
| DFRSHYAQLQ | SNIIEAINEL | LVELEGTTEN | IAAQALEHIH | SNEVIMTIGF | SRTVEAFLRE |
| 190 | 200 | 210 | 220 | 230 | 240 |
| AARKRKFHVI | VAECAPFCQG | HEMAVNLSKA | GIETTVMTDA | AIFAVMSRVN | KVIIGTKTIL |
| 250 | 260 | 270 | 280 | 290 | 300 |
| ANGALRAVAG | THTLALAAKH | HSTPLIVCAP | MFKLSPQFPN | EEDSFHKFVA | PEEVLPFTEG |
| 310 | 320 | 330 | 340 | 350 | |
| DILEKVSVHC | PVFDYVPPEL | ITLFISNIGG | NAPSYIYRLM | SELYHPDDHV | L |